GlassScriptPhysician profile
Elizabeth Spence
NPI 1770949596
$1,767.57
in general payments reported to CMS, 2019-2025
25 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $387 · 2024: $686 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $315.23 | 2024-2025 | |
| Lilly USA, LLC | $245.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $198.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.21 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $124.83 | 2023-2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $79.15 | 2024-2025 | Vowst, Zenpep |
| Glaxosmithkline, LLC. | $76.67 | 2023-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $49.32 | 2024-2025 | Airsupra |
| Gilead Sciences, INC. | $47.75 | 2024 | |
| Idorsia Pharmaceuticals US INC | $44.59 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $39.84 | 2023 | |
| Genzyme Corporation | $38.49 | 2023 | |
| Boston Scientific Corporation | $36.88 | 2025 | Wavewriter Alpha Prime 16 |
| Tandem Diabetes Care, INC. | $35.24 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $33.64 | 2024 | Evenity, Prolia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $32.44 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $30.30 | 2024 | Gardasil, Capvaxive, M-M-R II |
| Nestle Healthcare Nutrition INC. | $30.12 | 2023 | |
| Abbvie INC. | $26.69 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.29 | 2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $24.07 | 2025 | Gemtesa |
| Mannkind Corporation | $22.24 | 2025 | |
| Ibsa Pharma INC. | $21.20 | 2024 | Licart, Tirosint |
| Tolmar, INC. | $15.94 | 2024 | |
| Madrigal Pharmaceuticals | $14.95 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.